SYNAGEVA BIOPHARMA CORP Insider Trading for April 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SYNAGEVA BIOPHARMA CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in SYNAGEVA BIOPHARMA CORP for April 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 65.10 | 8,000 | 520,800 | 219,614 | 211.6 K to 219.6 K (+3.78 %) |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 65.10 | 8,000 | 520,800 | 8,180,521 | 8.2 M to 8.2 M (+0.10 %) |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 65.10 | 8,000 | 520,800 | 108,490 | 100.5 K to 108.5 K (+7.96 %) |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 65.10 | 8,000 | 520,800 | 1,744,065 | 1.7 M to 1.7 M (+0.46 %) |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 65.10 | 8,000 | 520,800 | 63,479 | 55.5 K to 63.5 K (+14.42 %) |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 65.10 | 8,000 | 520,800 | 173,213 | 165.2 K to 173.2 K (+4.84 %) |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 65.10 | 8,000 | 520,800 | 214,800 | 206.8 K to 214.8 K (+3.87 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 0.95 | 10,000 | 9,500 | 18,964 | |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 0.95 | 10,000 | 9,500 | 25,524 | 15.5 K to 25.5 K (+64.42 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 23.00 | 10,000 | 230,000 | 40,000 | |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 0.95 | 10,000 | 9,500 | 28,964 | |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 85.76 | 1,050 | 90,048 | 15,524 | 16.6 K to 15.5 K (-6.34 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 84.72 | 4,746 | 402,081 | 16,574 | 21.3 K to 16.6 K (-22.26 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 83.50 | 3,529 | 294,672 | 21,320 | 24.8 K to 21.3 K (-14.20 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 82.80 | 10,675 | 883,890 | 24,849 | 35.5 K to 24.8 K (-30.05 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 23.00 | 10,000 | 230,000 | 35,524 | 25.5 K to 35.5 K (+39.18 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 0.95 | 10,000 | 9,500 | 25,524 | 15.5 K to 25.5 K (+64.42 %) |